Show simple item record

dc.contributor.authorBowrin, Kevin
dc.contributor.authorBriere, Jean-Baptiste
dc.contributor.authorLévy, Pierre
dc.contributor.authorMillier, Aurélie
dc.contributor.authorTardu, Jean
dc.contributor.authorToumi, Mondher
dc.date.accessioned2021-01-25T13:19:46Z
dc.date.available2021-01-25T13:19:46Z
dc.date.issued2020-06
dc.identifier.issn2001-6689
dc.identifier.urihttps://basepub.dauphine.fr/handle/123456789/21537
dc.language.isoenen
dc.subjectAnticoagulantsen
dc.subjectatrial fibrillationen
dc.subjectcost-effectivenessen
dc.subjecteconomicen
dc.subjectreal-world evidenceen
dc.subjectstroke preventionen
dc.subject.ddc334en
dc.subject.classificationjelI.I1.I18en
dc.subject.classificationjelI.I1.I12en
dc.titleReal-world cost-effectiveness of rivaroxaban and apixaban vs VKA in stroke prevention in non-valvular atrial fibrillation in the UKen
dc.typeArticle accepté pour publication ou publié
dc.contributor.editoruniversityotherUniversité Aix-Marseille;France
dc.relation.isversionofjnlnameJournal of Market Access & Health Policy
dc.relation.isversionofjnlvol8en
dc.relation.isversionofjnlissue1en
dc.relation.isversionofjnldate2020-06
dc.relation.isversionofjnlpages1782164en
dc.relation.isversionofdoi10.1080/20016689.2020.1782164en
dc.relation.isversionofjnlpublisherTaylor & Francisen
dc.subject.ddclabelEconomie socialeen
dc.relation.forthcomingnonen
dc.relation.forthcomingprintnonen
dc.description.ssrncandidatenonen
dc.description.halcandidateouien
dc.description.readershiprechercheen
dc.description.audienceInternationalen
dc.relation.Isversionofjnlpeerreviewednonen
dc.relation.Isversionofjnlpeerreviewednonen
dc.date.updated2021-01-25T12:41:48Z
hal.person.labIds167303
hal.person.labIds73660
hal.person.labIds163517$$$559342
hal.person.labIds147877
hal.person.labIds147877
hal.person.labIds527022
hal.identifierhal-03120333*


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record